Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) and Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.
Profitability
This table compares Scinai Immunotherapeutics and Rhythm Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scinai Immunotherapeutics | N/A | N/A | N/A |
| Rhythm Pharmaceuticals | -69.03% | -171.16% | -43.00% |
Valuation & Earnings
This table compares Scinai Immunotherapeutics and Rhythm Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Scinai Immunotherapeutics | $1.31 million | 0.53 | -$8.31 million | ($95.34) | -0.01 |
| Rhythm Pharmaceuticals | $189.76 million | 41.56 | -$196.54 million | ($2.90) | -39.23 |
Scinai Immunotherapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 6.0% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and recommmendations for Scinai Immunotherapeutics and Rhythm Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scinai Immunotherapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Rhythm Pharmaceuticals | 1 | 3 | 18 | 0 | 2.77 |
Rhythm Pharmaceuticals has a consensus target price of $142.00, indicating a potential upside of 24.83%. Given Rhythm Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Scinai Immunotherapeutics.
Risk & Volatility
Scinai Immunotherapeutics has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.
Summary
Scinai Immunotherapeutics beats Rhythm Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
